UARK 2003-18, A Phase II Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma
This study will induce anti-myeloma responses in patients with high risk or relapsed myeloma
using combination chemo- and immunotherapy comprising sequentially: 1) lymphoid suppressive
conditioning to avoid rejection of the donor NK cells, 2) adoptive transfer of purified
KIR-ligand mismatched Natural Killer cells from a haplo-identical donor, and 3) autografting
two weeks after infusion of NK cells to ensure autologous reconstitution.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To induce anti-myeloma responses in patients with high risk or relapsed myeloma using combination chemo- and immunotherapy comprising sequentially.
Frits Van Rhee, M.D., Ph.D.
University of Arkansas for Medical Sciences/MIRT
United States: Food and Drug Administration
|University of Arkansas for Medical Sciences/MIRT||Little Rock, Arkansas 72205|